Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5793-5800

  Garrido Laguna, Ignacio ^a,d   Uson, Maria ^a   Rajeshkumar, N V ^a   Tan, Aik Choon ^a,e   De Oliveira, Elizabeth ^a   Karikari, Collins ^a   Villaroel, Maria C ^a   Salomon, Ana ^a   Taylor, Gretchen ^a   Sharma, Rajni ^a   Hruban, Ralph H ^a   Maitra, Anirban ^a   Laheru, Daniel ^a   Rubio Viqueira, Beleń ^b,c   Jimeno, Antonio ^a,e   Hidalgo, Manuel ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; GEMCITABINE; MUTANT PROTEIN; SMAD4 PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUDE MOUSE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS DUCTAL ADENOCARCINOMA; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SMAD4 GENE; STROMA; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; SMAD4 PROTEIN; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 80052470635     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0341     Document Type: Article

References (31)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-1617
2. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-1431 (Pubitemid 32522115)
3. Daniel V.C., Marchionni L., Hierman J.S., Rhodes J.T., Devereux W.L., Rudin C.M., et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-3373
4. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918-926 (Pubitemid 351206771)
5. Vonlaufen A., Joshi S., Qu C., Phillips P.A., Xu Z., Parker N.R., et al. Pancreatic stellate cells: Partners in crime with pancreatic cancer cells. Cancer Res 2008;68:2085-2093 (Pubitemid 351521780)
6. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461
7. Maitra A., Rajeshkumar N.V., Rudek M., Garrido-Laguna I., Laheru D., Iglesias J., et al. Nab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models. In:AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Boston; 2009.
8. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-1197 (Pubitemid 46711982)
9. Olive K.P., Tuveson D.A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12:5277-5287 (Pubitemid 44497240)
10. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806
11. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., DeSolms S.J., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-797
12. Rubio-Viqueira B., Jimeno A., Cusatis G., Zhang X., Iacobuzio-Donahue C., Karikari C., et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-4661 (Pubitemid 44297818)
13. Rubio-Viqueira B., Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009;85:217-221
14. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-15550 (Pubitemid 41528093)
15. Kaplan E.L., Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc 1958;53:457-481
16. Rasheed Z.A., Yang J., Wang Q., Kowalski J., Freed I., Murter C., et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102:340-351
17. Wilentz R.E., Su G.H., Dai J.L., Sparks A.B., Argani P., Sohn T.A., et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43. (Pubitemid 30644436)
18. Iacobuzio-Donahue C.A., Fu B., Yachida S., Luo M., Abe H., Henderson C.M., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806-1813
19. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54. (Pubitemid 36068681)
20. Charafe-Jauffret E., Ginestier C., Iovino F., Tarpin C., Diebel M., Esterni B., et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010;16:45-55.
21. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037
22. Blackford A., Serrano O.K., Wolfgang C.L., Parmigiani G., Jones S., Zhang X., et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009;15:4674-4679
23. Tascilar M., Skinner H.G., Rosty C., Sohn T., Wilentz R.E., Offerhaus G.J., et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-4121 (Pubitemid 34044636)
24. Nemati F., Sastre-Garau X., Laurent C., Couturier J., Mariani P., Desjardins L., et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010;16:2352-2362
25. John T., Kohler D., Pintilie M., Yanagawa N., Pham N.A., Li M., et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2011;17:134-141
26. Saadi A., Shannon N.B., Lao-Sirieix P., O'Donovan M., Walker E., Clemons N.J., et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A 2010;107:2177-2182
27. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-563 (Pubitemid 47525152)
28. Marchini C., Montani M., Konstantinidou G., Orrù R., Mannucci S., Ramadori G., et al. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One 2010;5:e14131.
29. Von Hoff D.D., Ramanathan R., Borad M., Laheru D., Smith L., Wood T., et al. SPARC correlation with response to gemcitabine (G) plus nabpaclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009;27:15s.
30. Dong X., Guan J., English J.C., Flint J., Yee J., Evans K., et al. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 2010;16:1442-1451
31. Marangoni E., Vincent-Salomon A., Auger N., Degeorges A., Assayag F., De Cremoux P., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007;13:3989-3998 (Pubitemid 47037607)